Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
N/A
88,719 Added 33.61%
352,707 $0
Q4 2023

Feb 14, 2024

SELL
N/A
-111,634 Reduced 29.72%
263,988 $0
Q2 2023

Aug 14, 2023

BUY
N/A
375,622 New
375,622 $0
Q4 2022

Feb 14, 2023

BUY
$0.0 - $9.95 $0 - $192,741
19,371 Added 93.74%
40,036 $259,000
Q3 2022

Nov 14, 2022

BUY
$8.57 - $11.57 $274 - $370
32 Added 0.16%
20,665 $184,000
Q2 2022

Aug 15, 2022

SELL
$8.84 - $11.64 $151,676 - $199,719
-17,158 Reduced 45.4%
20,633 $206,000
Q1 2022

May 16, 2022

BUY
$10.07 - $11.93 $269,896 - $319,747
26,802 Added 243.9%
37,791 $438,000
Q4 2021

Feb 14, 2022

SELL
$7.95 - $11.24 $699,027 - $988,310
-87,928 Reduced 88.89%
10,989 $122,000
Q3 2021

Nov 15, 2021

BUY
$9.22 - $12.44 $240,079 - $323,925
26,039 Added 35.73%
98,917 $912,000
Q2 2021

Aug 16, 2021

SELL
$9.91 - $12.78 $180,451 - $232,711
-18,209 Reduced 19.99%
72,878 $820,000
Q1 2021

May 17, 2021

SELL
$10.44 - $12.22 $395,968 - $463,480
-37,928 Reduced 29.4%
91,087 $966,000
Q4 2020

Feb 16, 2021

BUY
$9.3 - $11.77 $458,183 - $579,872
49,267 Added 61.78%
129,015 $1.4 Million
Q3 2020

Nov 16, 2020

BUY
$7.59 - $10.8 $344,927 - $490,806
45,445 Added 132.48%
79,748 $775,000
Q2 2020

Aug 14, 2020

SELL
$7.96 - $11.54 $480,919 - $697,212
-60,417 Reduced 63.78%
34,303 $273,000
Q1 2020

May 14, 2020

BUY
$7.69 - $11.68 $728,396 - $1.11 Million
94,720 New
94,720 $823,000
Q3 2019

Nov 14, 2019

SELL
$9.66 - $12.36 $162,152 - $207,474
-16,786 Closed
0 $0
Q2 2019

Aug 15, 2019

SELL
$9.32 - $12.98 $222,608 - $310,027
-23,885 Reduced 58.73%
16,786 $157,000
Q1 2019

May 14, 2019

BUY
$10.35 - $13.06 $420,944 - $531,163
40,671 New
40,671 $499,000

Others Institutions Holding LNDC

About LANDEC CORP \CA\


  • Ticker LNDC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 29,595,600
  • Description
  • Landec Corporation operates as a diversified health and wellness company. The company manufactures pharmaceutical-grade sodium hyaluronate (HA)-based biomaterials for primary use in the ophthalmic and orthopedic markets. It also provides product development services to its partners for HA-based, as well as non-HA based, aseptically formulated, a...
More about LNDC
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.